Epstein-Barr virus reactivation after COVID-19 vaccination in a young immunocompetent man: a case report.

Authors :: Herzum A
Trave I
D'Agostino F
Burlando M
Cozzani E
Parodi A
Source :: Clinical and experimental vaccine research [Clin Exp Vaccine Res] 2022 May; Vol. 11 (2), pp. 222-225. Date of Electronic Publication: 2022 May 31.
Publication Year :: 2022
Abstract: We present the case of a 24-year-old Caucasian man, who developed a scaly erythematous skin rash after the second dose of coronavirus disease 2019 (COVID-19) vaccination with Comirnaty (BNT162b2, BioNTech/Pfizer; Pfizer, New York, NY, USA) and proved positive for Epstein-Barr virus (EBV) reactivation. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines have been associated with an up-regulated T helper type 1-cell response, possibly favoring an immune system imbalance. Also, EBV reactivation has been postulated after COVID-19 vaccination, but only in the immunosuppressed. Noteworthy we report the first case of EBV viral reactivation associated with cutaneous manifestations in an immunocompetent patient after the COVID-19 vaccine.<br />Competing Interests: No potential conflict of interest relevant to this article was reported.<br /> (© Korean Vaccine Society.)

Full Text Access

Tools